BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 10741147)

  • 21. Current management of follicular lymphomas.
    Hiddemann W; Buske C; Dreyling M; Weigert O; Lenz G; Unterhalt M
    Br J Haematol; 2007 Jan; 136(2):191-202. PubMed ID: 17073892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mantle cell lymphoma: established therapeutic options and future directions.
    Lenz G; Dreyling M; Hiddemann W
    Ann Hematol; 2004 Feb; 83(2):71-7. PubMed ID: 14669040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
    Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV
    Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas.
    Tóthová E; Kafková A; Guman T; Stecová N; Fricová M
    Neoplasma; 2003; 50(1):22-5. PubMed ID: 12687274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Follicular lymphoma: a therapeutic update.
    Italiano A; Thyss A
    Bull Cancer; 2005 Oct; 92(10):E57-64. PubMed ID: 16266867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
    Nademanee A; Forman SJ
    Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
    Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
    Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current treatment of follicular low-grade lymphomas.
    Peterson BA
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):2-11. PubMed ID: 10561012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab therapy for indolent non-Hodgkin's lymphoma.
    Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current treatment of follicular and low-grade non-Hodgkin's lymphoma.
    Linch D
    Anticancer Drugs; 2001 Jun; 12 Suppl 2():S5-9. PubMed ID: 11508934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transplantation strategies for patients with follicular lymphoma.
    Buske C; Dreyling M; Unterhalt M; Hiddemann W
    Curr Opin Hematol; 2005 Jul; 12(4):266-72. PubMed ID: 15928482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improving outcomes in transplantation.
    Brugger W
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):23-6. PubMed ID: 12040531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients.
    Leahy MF; Turner JH
    Blood; 2011 Jan; 117(1):45-52. PubMed ID: 20864582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.
    Magni M; Di Nicola M; Devizzi L; Matteucci P; Lombardi F; Gandola L; Ravagnani F; Giardini R; Dastoli G; Tarella C; Pileri A; Bonadonna G; Gianni AM
    Blood; 2000 Aug; 96(3):864-9. PubMed ID: 10910898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2015 Aug; 90(8):739-45. PubMed ID: 26103436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL.
    Bachy E; Salles G
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):257-70. PubMed ID: 21658622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?
    Hamadani M
    Bone Marrow Transplant; 2013 Aug; 48(8):1013-21. PubMed ID: 23000653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.